2229. Impact of Elexacaftor/tezacaftor/ivacaftor on Utilization of Antibiotics at a Single Pediatric Cystic Fibrosis Center

BACKGROUND: Intravenous (IV) and oral (PO) antibiotics (ABX) are standard treatments for pulmonary exacerbations (PEx) in people with cystic fibrosis (pwCF). Frequent ABX use may lead to adverse events and ABX resistance. Cystic fibrosis transmembrane conductance regulator modulator treatments have...

Descripción completa

Detalles Bibliográficos
Autores principales: Elson, Elizabeth C, Lee, Brian R, Burns, Alaina N, Herigon, Joshua C, Wirtz, Ann, Duehlmeyer, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677398/
http://dx.doi.org/10.1093/ofid/ofad500.1851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677398/
http://dx.doi.org/10.1093/ofid/ofad500.1851

Ejemplares similares